reseligo 3,6 mg
zentiva k.s., Česká republika - goserelín - 44 - cytostatica
reseligo 10,8 mg
zentiva k.s., Česká republika - goserelín - 44 - cytostatica
zoladex depot 3,6 mg
astrazeneca ab, Švédsko - goserelín - 44 - cytostatica
zoladex la depot 10,8 mg
astrazeneca ab, Švédsko - goserelín - 44 - cytostatica
firmagon
ferring pharmaceuticals a/s - degarelix - prostatické nádory - endokrinná terapia - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
leuprorelin sandoz 5 mg implantát
sandoz pharmaceuticals d.d., slovinsko - leuprorelín - 56 - hormona (lieČiva s hormonÁlnou aktivitou)
leuprorelin sandoz 3,6 mg implantát
sandoz pharmaceuticals d.d., slovinsko - leuprorelín - 56 - hormona (lieČiva s hormonÁlnou aktivitou)
degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostatické nádory - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
porceptal 4 µg/ml injekčný roztok pre ošípané
intervet international b.v., holandsko - inj.
busol 0,004 mg/ml injekčný roztok pre hovädzí dobytok, kone, králiky
t.p. whelehan son & co., Írsko - inj.